Revolutionary Cancer Treatment Targets Dormant "Sleeper Cells" to Prevent Recurrence

Researchers at the University of Pennsylvania have made a groundbreaking discovery in cancer treatment by identifying and targeting dormant "sleeper cells" that can cause breast cancer to return and spread years after the original tumor is removed. This innovative approach, led by oncologist Dr. Angela DeMichele, has shown promising results in a small clinical trial, offering new hope for prevention and reducing the risk of cancer recurrence in high-risk breast cancer survivors.

Key Takeaways:

• A new clinical trial has identified and targeted dormant "sleeper cells" in high-risk breast cancer survivors, showing a significantly lower-than-expected recurrence rate.
• The team, led by Dr. Angela DeMichele, has advanced a method to identify and attack these disseminated tumor cells (DTCs) that break away from the main tumor and lie undetected in areas such as the bone marrow.
• The small Phase 1/2 trial included 51 women, with median follow-up of three years, and demonstrated disease-free survival rates of 91.7% for patients taking hydroxychloroquine, 92.9% for those taking everolimus, and 100% for those taking a combination of the two drugs.
• Two participants experienced a cancer recurrence after a seven-year follow-up, a rate far below what was statistically expected for this high-risk group.
• The research provides vital reassurance to patients like Illeana Casiano-Vazquez, who was treated for triple-negative breast cancer and had a 25% chance of cancer returning within five years.
• Researchers now plan larger clinical trials to confirm their findings and explore whether this targeted approach can be applied to prevent recurrence in other types of cancer.

Statistics:

• Disease-free survival rates at three years: 91.7% for patients taking hydroxychloroquine, 92.9% for those taking everolimus, and 100% for those taking a combination of the two drugs.
• Two participants experienced a cancer recurrence after a seven-year follow-up, a rate of 3.9% (2/51).
• Initial chemotherapy and double mastectomy were performed on all patients, followed by treatments to eliminate dormant cancer cells.
• Participants were followed for a median of three years, with half being followed longer and half for a shorter time.

Sources:

• CBS News, Oct. 22, 2025
• Nature Medicine, Sept. 2, 2025
• The National Cancer Institute provides information on new developments and clinical trials for breast cancer.